

# Supplementary Material

## Funding and Acknowledgements

**Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study (ATBC1 and ATBC2):** The ATBC Study is supported by the Intramural Research Program of the U.S. National Cancer Institute, National Institutes of Health, and by U.S. Public Health Service contract HHSN261201500005C from the National Cancer Institute, Department of Health and Human Services.

**Beta-Carotene and Retinol Efficacy Trial (CARET):** This work was supported by grants from the National Institutes of Health (U01 CA63673 and UM1 CA167462).

**Breakthrough Generations Study (BGS):** We thank Breast Cancer Now and the Institute of Cancer Research for support and funding of the Breakthrough Generations Study. We acknowledge NHS funding to the Royal Marsden/ICR NIHR Biomedical Research Centre.

**Cancer Prevention Study-II (CPS-II):** The American Cancer Society funds the creation, maintenance and updating of the Cancer Prevention Study II (CPS-II) cohort. We acknowledge the contribution to this study from central cancer registries supported through the Centers for Disease Control and Prevention's National Program of Cancer Registries, as well as cancer registries supported by the National Cancer Institute's Surveillance Epidemiology and End Results program. The views expressed here are those of the authors and do not necessarily represent the American Cancer Society or the American Cancer Society – Cancer Action Network.

**CLUE II: Campaign Against Cancer and Heart Disease (CLUE II):** Funding to support CLUE II, for studies on colorectal cancer in the cohort, and for the investigators were from grants from the National Cancer Institute (U01 CA86308, Early Detection Research Network; P30 CA006973), National Institute on Aging (U01 AG18033), and the American Institute for Cancer Research. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the US government.

**European Investigation into Cancer and Nutrition (EPIC):** Grant funding for the EPIC study on vitamin D and colorectal cancer was provided by the World Cancer Research Fund (WCRF, London, UK; grant number 2005/12; PIs: M. Jenab / E. Riboli). The coordination of EPIC is financially supported by the European Commission (DG-SANCO) and the International Agency for Research on Cancer (IARC-WHO). The national cohorts are supported by Danish Cancer Society (Denmark); Ligue Contre le Cancer, Institut Gustave Roussy, Mutuelle Générale de l'Éducation Nationale, Institut National de la Santé et de la Recherche Médicale (INSERM) (France); Deutsche Krebshilfe, Deutsches Krebsforschungszentrum and Federal Ministry of Education and Research (Germany); the Hellenic Health Foundation (Greece); Associazione Italiana per la Ricerca sul Cancro-AIRC-Italy and National Research Council (Italy); Dutch Ministry of Public Health, Welfare and Sports (VWS), Netherlands Cancer Registry (NKR), LK Research Funds, Dutch Prevention Funds, Dutch ZON (Zorg Onderzoek Nederland), World Cancer Research Fund (WCRF), Statistics Netherlands (The Netherlands); Nordic Centre of Excellence Programme on Food, Nutrition and Health (Norway); Health Research Fund (FIS), PI13/00061 to Granada, Regional Governments of Andalucía, Asturias, Basque Country, Murcia (no. 6236) and Navarra, ISCIII RETIC (RD06/0020) (Spain); Swedish Cancer Society, Swedish Scientific Council and County Councils of Skåne and Västerbotten (Sweden); Cancer Research UK (14136 to EPIC-Norfolk; C570/A16491 to EPIC-Oxford), Medical Research Council (1000143 to EPIC-Norfolk) (United Kingdom).

**Health Professionals Follow-up Study (HPFS):** This work was supported by grants from the National Institutes of Health (UM1 CA167552, P01 CA55075), the Entertainment Industry Foundation, and the National Colorectal Cancer Research Alliance. We also would like to thank the following state cancer registries for their help: AL, AZ, AR, CA, CO, CT, DE, FL, GA, ID, IL, IN, IA, KY, LA, ME, MD, MA, MI, NE, NH, NJ, NY, NC, ND, OH, OK, OR, PA, RI, SC, TN, TX, VA, WA, WY. The authors assume full responsibility for analyses and interpretation of these data.

**Hormones and Diet in the Etiology of Breast Cancer Study (ORDET):** This study was supported by the Italian Association for Cancer Research (AIRC).

**Janus Serum Bank (JANUS):** We sincerely thank the Cancer Registry of Norway and the Norwegian Cancer Society for financial funding.

**Japan Public Health Center-based Prospective Study (JPHC):** This work was supported by the National Cancer Center Research and Development Fund (since 2011) and a grant-in-aid from Cancer Research (1989–2010) from the Ministry of Health, Labor, and Welfare of Japan.

**Multiethnic Cohort Study (MEC):** This work was supported by the National Institutes of Health (P01 CA33619 and U01 CA164973).

**New York University Women's Health Study (NYU WHS):** This work was supported by grants from the National Institutes of Health (R01 CA098661, UM1 CA182934 and center grants P30 CA016087 and P30 ES000260).

**Nurses' Health Study (NHS):** This work was supported by the National Institutes of Health grants UM1 CA186107, R01 CA49449 and P01 CA87969, the Entertainment Industry Foundation, and the National Colorectal Cancer Research Alliance. We would like to thank the following state cancer registries for their help: AL, AZ, AR, CA, CO, CT, DE, FL, GA, ID, IL, IN, IA, KY, LA, ME, MD, MA, MI, NE, NH, NJ, NY, NC, ND, OH, OK, OR, PA, RI, SC, TN, TX, VA, WA, WY. The authors assume full responsibility for analyses and interpretation of these data.

**Physicians' Health Study (PHS):** The Physicians' Health Study is supported by investigator-initiated grants from the National Institutes of Health (CA097193, CA34944, CA40360, HL26490, and HL34595) and Pfizer Inc.

**Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial (PLCO):** This research was supported by the Intramural Research Program of the Division of Cancer Epidemiology and Genetics, National Cancer Institute and by contracts from the Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Department of Health and Human Services.

**Women's Health Initiative (WHI):** The WHI program is funded by the National Heart, Lung, and Blood Institute, National Institutes of Health, U.S. Department of Health and Human Services through contracts HHSN268201100046C, HHSN268201100001C, HHSN268201100002C, HHSN268201100003C, HHSN268201100004C, HHSN271201100004C, and CCSG P 30 CA23074.

**Women's Health Study (WHS):** This work was supported by grants from the National Institutes of Health (CA047988, HL043851, HL080467).

## Supplementary Methods

### Additional detail on calibration of previously measured 25(OH)D and season standardization:

For each study that had previously measured 25(OH)D concentrations, individual 25(OH)D levels were first calibrated to the same assay used for the newly measured studies (direct, competitive chemiluminescence immunoassay at Heartland Assays, LLC) according to  $Y_{calibrated} = \hat{a} + \hat{b}Y_{original}$ , where the estimates  $\hat{a}$  and  $\hat{b}$  were obtained by regressing Heartland Assays 25(OH)D on the original 25(OH)D values for 29 calibration samples<sup>1</sup>. In each study, approximately three controls had been selected within each decile of the study-specific 25(OH)D distribution to serve as calibration samples and were re-assayed at Heartland Assays. Variances for the continuous 25(OH)D analyses were increased to account for laboratory error in the calibration process; variances for the categorical analyses did not need to be similarly adjusted<sup>1</sup>. In studies where the 25(OH)D concentrations were newly measured for this project by Heartland Assays, no calibration was required.

For most studies, seasonal variation in 25(OH)D concentrations followed a sinusoidal distribution, with lowest values in the winter and highest in the summer. To remove variation in circulating 25(OH)D due to season of blood collection, individual residuals from the study-specific sine-cosine function,

$$\{\gamma_0 + \gamma_1 \sin(2\pi t / 52) + \gamma_2 \cos(2\pi t / 52) + \gamma_3 \sin(4\pi t / 52) + \gamma_4 \cos(4\pi t / 52), \text{ fitted to controls}\}$$

were added to  $\hat{\gamma}_0$ . Here  $t = 1, 2, \dots, 52$  indexes the week of blood draw. Because the sinusoidal components integrate to zero over the year,  $\hat{\gamma}_0$  represents the study-specific average 25(OH)D over the entire year.

### Quality control outlier criteria:

The following were used to evaluate quality control: 1) the Westgard multi-rule quality control criteria<sup>2</sup> and 2) examination of study-specific within-batch, between-batch, and overall coefficients of variation (CVs) and intraclass correlation coefficients for the three National Institute of Standards and Technology (NIST) standards and the study-specific quality control samples. For the batches that violated the Westgard rules or had study-specific overall CVs or batch-specific CVs larger than 10% (15% for NIST standard 1), the circulating 25(OH)D distribution of the control samples in that batch was compared with the 25(OH)D distributions for other batches from the same study. In addition, visual examination using Q-Q plots was used to identify potential outliers. No batches or outliers were removed on the basis of the above criteria.

### Matching criteria for each cohort:

In addition to all cohorts matching cases and controls on age, date of blood draw, and sex (if applicable), the following cohorts included additional matching factors as listed:

ATBC1: Study clinic

BGS: Ethnicity, year of entry into cohort, number of days between blood draw and processing

CARET: Race

CLUE II: Race, availability of food frequency questionnaire, hours since last meal

CPS-II: Race

EPIC: Study center, fasting status at blood draw, time of day at blood draw; among women, menopausal status, phase of menstrual cycle, and usage of menopausal hormone therapy

JPHC: Study center, fasting status at blood draw

MEC: Race, study center, fasting status at blood draw, time of day at blood draw

NYUWHS: Race, menopausal status, number of blood draws

PHS: Smoking status

PLCO: Race

WHI: Race, latitude of clinical center

WHS: Race, fasting status at blood draw, time of day at blood draw

### **Covariates included in fully adjusted multivariable model:**

The fully adjusted model (Model 3) included the following established and suspected colorectal cancer risk factors: body mass index (<20, 20-<22.5, 22.5-<25, 25-<27.5, 27.5-<30, ≥30 kg/m<sup>2</sup>); physical activity (study-specific tertiles of metabolic equivalents in hours/week, if available, or low, moderate, high); race (white, black, Asian, other, for studies that did not match on race); family history of colorectal cancer (yes, no); alcohol consumption (men: 0, >0-<5, 5-<15, 15-<30, ≥30 g/d; women: 0, >0-<5, 5-<15, ≥15 g/d); smoking status (never, former, current); aspirin and/or non-steroidal anti-inflammatory drug use (yes, no for regular use); and in women, menopausal status and menopausal hormone therapy (postmenopausal/never hormone use, postmenopausal/former hormone use, postmenopausal/current hormone use, postmenopausal/missing hormone use, premenopausal, perimenopausal or missing menopausal status). For the European Prospective Investigation into Cancer and Nutrition, this variable was modeled as postmenopausal/not current hormone use and postmenopausal/current hormone use, and for the Japan Public Health Center-based Prospective Study, this variable was modeled as postmenopausal/never hormone use and postmenopausal/ever hormone use). All covariates included a missing category.

In Figure 3, condensed forms of the following covariates were used in all stratified analyses due to smaller numbers of subjects in certain strata (BMI: <25, 25-<30, ≥30 kg/m<sup>2</sup>; alcohol consumption: in men, 0, >0-<30, ≥30 g/day; in women, 0, >0-<15, ≥15 g/day).

### **Covariates available for each cohort:**

With the exception of aspirin/non-steroidal anti-inflammatory drug use which was only available from nine cohorts, data for most of the other covariates were available for nearly all the cohorts.

All cohorts have data on age, date of blood draw, race (data available or cohort all one race), body mass index and smoking status; 14 have physical activity (ATBC, BGS, CPS-II, EPIC, HPFS, JANUS, JPHC, MEC, NHS, NYUWHS, PHS, PLCO, WHI, and WHS); 12 have family history of colorectal cancer (ATBC, BGS, CARET, CPS-II, HPFS, JPHC, MEC, NHS, NYUWHS, PLCO, WHI, and WHS); 16 have alcohol consumption (ATBC, BGS, CARET, CLUE II, CPS-II, EPIC, HPFS, JPHC, MEC, NHS, NYUWHS, ORDET, PHS, PLCO, WHI, and WHS); 9 have aspirin/non-steroidal anti-inflammatory drug use (ATBC, CLUE II, CPS-II, HPFS, MEC, NHS, PLCO, WHI, and WHS); 12 (of 13 that included women) have menopausal status and information on menopausal hormone therapy (BGS, CLUE II, CPS-II, EPIC, JPHC, MEC, NHS, NYUWHS, ORDET, PLCO, WHI, and WHS).

Except for family history (missing for 11% of participants, 10% of women, 13% of men), the percentage of missing data for each covariate was ≤9% among the studies that measured that covariate, with most studies having ≤5% missing data. In the analyses, all covariates included a missing category.

### **Exclusions applied prior to analysis:**

The initial sample included 6,044 cases and 7,598 controls. CARET women were excluded from the initial sample due to having fewer than 50 cases. We excluded cases and controls with a missing vitamin D value (n=162), a missing date of blood draw or date of colorectal cancer diagnosis (n=24), a history of cancer before blood draw or between blood draw and case diagnosis date or diagnosis age (n=314), control blood draw after case diagnosis date or diagnosis age (n=22), invalid ICD code (n=93), and tumor behavior code of “malignant, metastatic site”, “uncertain whether benign or malignant”, or “benign” (n=208), and duplicate ID or missing matched case (n=6), leaving 5,706 cases and 7,107 controls for analysis.

## **Exclusions based on study-specific sample sizes:**

### Figure 1 and Table 3:

JPHC women and men were excluded from the <30 and 30-<40 nmol/L categories because there were no cases in these categories. ORDET was excluded from the 75-<87.5 nmol/L category because there was only 1 case in this category. JPHC women and ORDET were excluded from the  $\geq 100$  nmol/L category because of small case numbers in this category (1 and 0 cases, respectively).

### Stratum-specific exclusions for Figure 3:

*Age at blood draw:* CPS-II women and men and MEC women and men were excluded from the <60 years stratum because of small case numbers. JANUS men were excluded from the  $\geq 60$  years stratum because of small case numbers.

*Age at diagnosis:* CPS-II women and men and MEC women were excluded from the <67 years stratum because of small case numbers.

*Race:* JPHC women and men were excluded from the White stratum because there were no cases and controls in this stratum. ATBC1, ATBC2, BGS, EPIC women and men, JANUS women and men, JPHC women and men, and ORDET were excluded from the Black stratum because there were no cases and controls in this stratum. ATBC1, ATBC2, BGS, CLUE II women and men, CPS-II women, EPIC women and men, JANUS women and men, and ORDET were excluded from the Asian stratum because there were no cases and controls in this stratum.

*Physical activity:* CARET men, CLUE II women and men and ORDET were excluded from these analyses because this variable was not measured in these studies, and MEC women were excluded from these analyses because of small case numbers in all strata. JPHC women were excluded from the low stratum because of small case numbers. BGS was excluded from the medium stratum because of small case numbers. ATBC1, ATBC2, and BGS were excluded from the high stratum because of small case numbers.

*Menopausal status:* JANUS women were excluded from these analyses because this variable was not measured in this study. CPS-II women, NHS, PLCO women, and WHI were excluded from the pre-menopausal stratum because there were no cases and controls in this stratum. BGS, CLUE II women, and MEC women were excluded from the pre-menopausal stratum because of small case numbers.

*Menopausal hormone therapy use:* JANUS women were excluded from these analyses because this variable was not measured and JPHC women were excluded from these analyses because menopausal hormone therapy use was collected as ever/never. BGS, CLUE II women, and MEC women were excluded from the current stratum because of small numbers and NYUWHS and ORDET were excluded from the current stratum because all participants in these cohorts could not be current users of menopausal hormone therapy based on cohort-specific eligibility criteria.

*Dietary calcium:* BGS, JANUS women and men, and PHS were excluded from these analyses because this variable was not measured.

*Smoking status:* JPHC women were excluded from the ever smoking stratum because of small case numbers. CARET men were excluded from the never smoking stratum because of small case numbers and ATBC1 and ATBC2 were excluded from the never smoking stratum because all participants in these cohorts were smokers.

*Alcohol intake:* JANUS was excluded from these analyses because this variable was not measured. ATBC1, BGS, CLUE II women and men, and PHS were excluded from the no intake stratum because of small case numbers. BGS, JPHC women and men, MEC women, and ORDET were excluded from the low intake (women: >0-<7 g/d; men: >0-<14 g/d) stratum because of small case numbers. CLUE II women and men, JPHC women, MEC women, and PHS were excluded from the high intake (women:  $\geq 7$  g/d; men:  $\geq 14$  g/d) stratum because of small case numbers.

*Season of blood draw:* CLUE II women and men were excluded from the winter stratum because of small case numbers.

*Latitude:* ATBC1, ATBC2, BGS, CLUE II women and men, EPIC women and men, JANUS women and men, ORDET, PLCO women and men were excluded from the <35<sup>0</sup> stratum because there were no participants residing in this latitude category, and CPS-II women, NYUWHS, and CARET men were excluded from the <35<sup>0</sup> stratum because of small case numbers. ATBC1, ATBC2, BGS, JANUS women and men, and ORDET were excluded from the 35-42<sup>0</sup> stratum because there were no participants residing in this latitude category, and MEC women and men were excluded from the 35-42<sup>0</sup> stratum because there were no cases residing in this latitude category. CLUE II women and men, JPHC women and men, MEC women and men were excluded from the >42<sup>0</sup> stratum because there were no participants residing in this latitude category, and NYUWHS was excluded from the >42<sup>0</sup> stratum because of small case numbers.

*Region:* U.S. cohorts include CARET, CLUE II, CPS-II, HPFS, MEC, NHS, NYUWHS, PHS, PLCO, WHI, and WHS. Studies outside of the U.S. include ATBC1, ATBC2, BGS, EPIC, JANUS, JPHC, and ORDET.

*Tumor stage:* BGS was excluded from the stage I/II stratum because of small case numbers. BGS, JPHC men, and MEC women and men were excluded from the stage III/IV stratum because of small case numbers.

*Tumor subsite:* CARET men, JANUS women and men, MEC women and men, and PLCO women were excluded from the rectum cancer analyses because of small case numbers. CARET men were excluded from the proximal colon cancer analyses because of small case numbers. BGS, CARET men, and MEC women were excluded from the distal colon cancer analyses because of small case numbers.

*Time to diagnosis:* ATBC2, CLUE II women and men, JANUS women and men, NYUWHS, ORDET, PHS, and WHS were excluded from the ≤2 years stratum because of small case numbers. ATBC2, JANUS women and men, MEC women, and ORDET were excluded from the >2-5 years stratum because of small case numbers. BGS and MEC women and men were excluded from the >5 years stratum because of small case numbers.

#### **Exclusions for Supplementary Table 2:**

JPHC women and men were excluded from quintile 1 of all subsite analyses because there were no colorectal cancer cases in this category. BGS and CARET men were excluded from all proximal colon cancer analyses because of small cases numbers. BGS, CARET men, and MEC women were excluded from all distal colon cancer analyses because of small case numbers. CPS-II women were excluded from quintile 1 and ATBC1 was excluded from quintile 5 of the distal colon cancer analyses because of small cases numbers in these categories. CARET men, CPS-II men, JANUS women and men, MEC women and men, and PLCO women were excluded from all rectal cancer analyses because of small cases numbers. ORDET was excluded from quintile 5 of the rectal cancer analyses because there were no cases in this category.

#### **References:**

1. Gail MH, Wu J, Wang M, et al. Calibration and seasonal adjustment for matched case-control studies of vitamin D and cancer. *Stat Med.* 2016;35(13):2133-2148.
2. Westgard JO, Groth T, Aronsson T, Falk H, de Verdier CH. Performance characteristics of rules for internal quality control: probabilities for false rejection and error detection. *Clin Chem.* 1977;23(10):1857-1867.

**Supplementary Table 1. Comparison of Pooled Multivariable-Adjusted Relative Risks for 25(OH)D and Colorectal Cancer from 2-Stage Models Combining Study-Specific Results Using Random and Fixed Effects Models, and from 1-Stage, Aggregated Models Pooling all Primary Data.**

Consortium-Wide, Sex-Specific Quintiles of Circulating 25(OH)D*							
Model	Q1	Q2	RR (95% CI) Q3 <sup>†</sup>	Q4	Q5	<i>P</i> <sub>trend</sub> <sup>‡</sup>	RR (95% CI) Q5 vs Q1
<b>Overall</b>							
Cases/controls	1519/1421	1247/1421	1094/1423	957/1421	889/1421		
Multivariable Model <sup>§</sup>							
Random effects <sup>¶</sup>	1.15 (0.97 to 1.38)	0.98 (0.83 to 1.16)	1.00	0.92 (0.79 to 1.07)	0.78 (0.65 to 0.94)	<.001	0.68 (0.56 to 0.82) <sup>¶</sup>
Fixed effects	1.20 (1.04 to 1.38)	1.02 (0.89 to 1.15)	1.00	0.93 (0.81 to 1.06)	0.79 (0.69 to 0.91)	<.001	0.69 (0.58 to 0.81) <sup>¶</sup>
Aggregated	1.17 (1.04 to 1.32)	1.02 (0.91 to 1.14)	1.00	0.93 (0.82 to 1.05)	0.83 (0.73 to 0.94)	<.001	0.71 (0.62 to 0.81)
<b>Women</b>							
25(OH)D (nmol/L)	< 37	37- <49	49- <59	59- <72	≥ 72		
Cases/controls	822/706	654/705	574/707	476/706	422/705		
Multivariable Model <sup>§</sup>							
Random effects <sup>¶</sup>	1.21 (0.97 to 1.52)	1.00 (0.82 to 1.23)	1.00	0.83 (0.66 to 1.05)	0.67 (0.54 to 0.81)	<.001	0.56 (0.45 to 0.71) <sup>¶</sup>
Fixed effects	1.25 (1.03 to 1.53)	1.02 (0.86 to 1.22)	1.00	0.86 (0.71 to 1.03)	0.67 (0.54 to 0.81)	<.001	0.56 (0.45 to 0.71) <sup>¶</sup>
Aggregated	1.25 (1.05 to 1.48)	1.03 (0.87 to 1.20)	1.00	0.87 (0.74 to 1.03)	0.72 (0.60 to 0.86)	<.001	0.57 (0.47 to 0.69)
<b>Men</b>							
25(OH)D (nmol/L)	< 41	41- <53	53- <63	63- <76	≥ 76		
Cases/controls	697/715	593/716	520/716	481/715	467/716		
Multivariable Model <sup>§</sup>							
Random effects <sup>¶</sup>	1.12 (0.84 to 1.49)	0.98 (0.75 to 1.29)	1.00	1.01 (0.83 to 1.22)	0.93 (0.69 to 1.25)	.20	0.82 (0.61 to 1.10) <sup>¶</sup>
Fixed effects	1.15 (0.94 to 1.40)	1.00 (0.84 to 1.21)	1.00	1.01 (0.84 to 1.22)	0.94 (0.77 to 1.15)	.20	0.86 (0.67 to 1.09) <sup>¶</sup>
Aggregated	1.08 (0.91 to 1.29)	1.02 (0.86 to 1.20)	1.00	0.98 (0.83 to 1.17)	0.93 (0.78 to 1.11)	.13	0.86 (0.71 to 1.04)

Abbreviations: 25(OH)D, 25-Hydroxyvitamin D; RR, relative risk; 95% CI, 95% confidence interval; Q1-5, quintile.

\*Consortium-wide, sex-specific quintiles are based on newly measured and calibrated season-standardized circulating 25(OH)D. Quintile cut-points are based on the distributions in the controls separately for each sex, as shown.

<sup>†</sup>Quintile 3 is used as the referent category because one cohort (JPHC), with no cases in consortium-wide quintile 1, would drop from the analysis.

<sup>‡</sup>*P*-value, two-sided test for trend calculated using a continuous variable based on the median 25(OH)D in each quintile.

<sup>§</sup>Multivariable model (equivalent to Model 3 in Table 2), conditioned on study-specific matching factors (see Supplementary Material), including date of blood draw and age, and additionally adjusted for body mass index (<20, 20-<22.5, 22.5-<25, 25-<27.5, 27.5-<30, ≥30 kg/m<sup>2</sup>); physical activity (study-specific tertiles of metabolic equivalents in hours/week, if available, or low, moderate, high); race (white, black, Asian, other, for studies that did not match on race); family history of colorectal cancer (yes, no); alcohol consumption (men: 0, >0-<5, 5-<15, 15-<30, ≥30 g/d; women: 0, >0-<5, 5-<15, ≥15 g/d); smoking status (never, former, current); aspirin and/or non-steroidal anti-inflammatory drug use (yes, no for regular use, available for 9 cohorts only); and in women, menopausal status and menopausal hormone therapy (postmenopausal/never hormone use, postmenopausal/former hormone use, postmenopausal/current hormone use, postmenopausal/missing hormone use, premenopausal, perimenopausal or missing menopausal status). For the EPIC, this variable was modeled as postmenopausal/not current hormone use and postmenopausal/current hormone use, and for the JPHC, this was modeled as postmenopausal/never hormone use and postmenopausal/ever hormone use). All covariates included a missing category.

<sup>¶</sup>The results for comparison of quintiles 1, 2, 4 and 5 with quintile 3 from the 2-stage random effects model are the same as those presented in Model 3, Table 2.

<sup>¶</sup>Excluding one cohort (JPHC), with no cases in consortium-wide quintile 1.

**Supplementary Table 2. Pooled Associations of Sex-Specific, Consortium-Wide Quintiles of 25(OH)D with Colorectal Cancer by Subsite\***

Consortium-Wide, Sex-Specific Quintiles of Circulating 25(OH)D <sup>†</sup>									
Model	Q1	Q2	RR (95% CI) Q3 <sup>‡</sup>	Q4	Q5	<i>P</i> <sub>trend</sub> <sup>§</sup>	<i>P</i> <sub>Het by Study</sub> <sup>¶</sup>	<i>P</i> <sub>Het by Sex</sub> <sup>¶</sup>	<i>P</i> <sub>Common Effects by Subsite</sub>
<b>Colon Cancer</b>									
<b>Overall</b>									
Cases/controls	1,067/992	889/1,024	811/1,018	703/1,065	696/1,073				
Multivariable model <sup>††</sup>	1.12 (0.92 to 1.37)	0.93 (0.77 to 1.14)	1.00	0.85 (0.70 to 1.03)	0.79 (0.65 to 0.96)	.001	.16, .13	.36, .05	.19, .62 <sup>#</sup>
<b>Women</b>									
25(OH)D (nmol/L)	< 37	37- <49	49- <59	59- <72	≥ 72				
Cases/controls	614/518	493/538	430/517	365/540	344/570				
Multivariable model <sup>††</sup>	1.27 (1.01 to 1.60)	0.98 (0.76 to 1.26)	1.00	0.79 (0.59 to 1.06)	0.66 (0.53 to 0.83)	<.001	.48, .85		.73, .74 <sup>#</sup>
<b>Men</b>									
25(OH)D (nmol/L)	< 41	41- <53	53- <63	63- <76	≥ 76				
Cases/controls	453/474	396/486	381/501	338/525	352/503				
Multivariable model <sup>††</sup>	1.01 (0.73 to 1.40)	0.89 (0.65 to 1.22)	1.00	0.91 (0.71 to 1.16)	0.93 (0.67 to 1.29)	.46	.08, .04		.16, .68 <sup>#</sup>
<b>Proximal Colon</b>									
<b>Overall</b>									
Cases/controls	518/490	453/498	441/528	357/561	364/616				
Multivariable model <sup>††</sup>	1.05 (0.78 to 1.41)	0.88 (0.68 to 1.14)	1.00	0.78 (0.57 to 1.06)	0.65 (0.48 to 0.90)	<.001	.16, .05	.76, .03	.38, .11 <sup>**</sup>
<b>Women</b>									
25(OH)D nmol/L	< 37	37- <49	49- <59	59- <72	≥ 72				
Cases/controls	326/297	276/294	258/284	195/309	198/352				
Multivariable model <sup>††</sup>	1.00 (0.67 to 1.50)	0.77 (0.52 to 1.12)	1.00	0.65 (0.42 to 1.00)	0.49 (0.31 to 0.76)	<.001	.20, .12		.30, .14 <sup>**</sup>
<b>Men</b>									
25(OH)D (nmol/L)	< 41	41- <53	53- <63	63- <76	≥ 76				
Cases/controls	192/193	177/204	183/244	162/252	166/264				
Multivariable model <sup>††</sup>	1.09 (0.68 to 1.75)	0.99 (0.71 to 1.40)	1.00	0.94 (0.60 to 1.47)	0.89 (0.59 to 1.34)	.06	.19, .24		.87, .46 <sup>**</sup>
<b>Distal Colon</b>									
<b>Overall</b>									
Cases/controls	409/384	329/398	272/393	280/418	261/376				
Multivariable model <sup>††</sup>	1.31 (0.88 to 1.95)	1.09 (0.80 to 1.49)	1.00	1.01 (0.76 to 1.34)	0.97 (0.68 to 1.39)	.13	.14, .20	.38, .34	
<b>Women</b>									
25(OH)D (nmol/L)	< 37	37- <49	49- <59	59- <72	≥ 72				
Cases/controls	215/180	171/181	129/185	136/186	108/168				
Multivariable model <sup>††</sup>	1.48 (0.79 to 2.78)	1.27 (0.83 to 1.94)	1.00	1.02 (0.66 to 1.58)	0.80 (0.49 to 1.30)	.01	.15, .60		
<b>Men</b>									
25(OH)D nmol/L	< 41	41- <53	53- <63	63- <76	≥ 76				
Cases/controls	194/204	158/217	143/208	144/232	153/208				
Multivariable model <sup>††</sup>	1.16 (0.69 to 1.96)	0.96 (0.61 to 1.52)	1.00	1.00 (0.69 to 1.45)	1.15 (0.66 to 1.99)	.97	.24, .07		
<b>Rectal Cancer</b>									
<b>Overall</b>									
Cases/controls	423/398	318/356	255/372	222/309	149/275				
Multivariable model <sup>††</sup>	1.44 (1.05 to 1.98)	1.11 (0.79 to 1.55)	1.00	1.12 (0.78 to 1.59)	0.88 (0.61 to 1.27)	.01	.66, .40	.90, .25	
<b>Women</b>									
25(OH)D (nmol/L)	< 37	37- <49	49- <59	59- <72	≥ 72				
Cases/controls	195/177	145/154	133/176	105/151	63/119				
Multivariable model <sup>††</sup>	1.41 (0.84 to 2.36)	0.88 (0.45 to 1.74)	1.00	0.87 (0.44 to 1.72)	0.58 (0.26 to 1.26)	.02	.48, .19		
<b>Men</b>									
25(OH)D (nmol/L)	< 41	41- <53	53- <63	63- <76	≥ 76				
Cases/controls	228/221	173/202	122/196	117/158	86/156				
Multivariable model <sup>††</sup>	1.46 (0.98 to 2.18)	1.18 (0.81 to 1.71)	1.00	1.34 (0.89 to 2.02)	1.05 (0.67 to 1.65)	.22	.58, .75		

Abbreviations: 25(OH)D, 25-Hydroxyvitamin D; RR, relative risk; 95% CI, 95% confidence interval; Q1-5, quintile; Het, heterogeneity.

\*Colon cancer was defined using International Classification of Diseases Oncology (ICD-O) codes: C18.0, C18.2–C18.9, with cecum, ascending colon, hepatic flexure, transverse colon and splenic flexure comprising proximal colon and descending and sigmoid colon comprising distal colon. Cancers of the recto-sigmoid junction (C19.9) and rectum (C20.9) comprised cancers of the rectum.

<sup>†</sup>Consortium-wide, sex-specific quintiles are based on newly measured and calibrated season-standardized circulating 25(OH)D. Quintile cut-points are based on the distributions in the controls, separately for each sex, as shown.

\*Quintile 3 is used as the referent category because one cohort (JPHC), with no cases in consortium-wide quintile 1, would drop from the analysis.

<sup>§</sup>*P*-value, two-sided test for trend calculated using a continuous variable based on the median 25(OH)D in each quintile.

<sup>†</sup>*P*-value, two-sided test for between-study heterogeneity. Results are for quintile 1 and quintile 5, respectively.

<sup>‡</sup>*P*-value, two-sided test for between-study heterogeneity due to sex. Results are for quintile 1 and quintile 5, respectively.

<sup>#</sup>*P*-value, two-sided test for common effects by subsite for colon *vs* rectum cancer. Results are for quintile 1 and quintile 5, respectively.

<sup>\*\*</sup>*P*-value, two-sided test for common effects by subsite for proximal *vs* distal colon cancer. Results are for quintile 1 and quintile 5, respectively.

<sup>††</sup>This model is similar to model 3 in Table 2, conditioned on study-specific matching factors (see Supplemental Material), including date of blood draw and age, and additionally adjusted for body mass index (<25, 25-<30, ≥30 kg/m<sup>2</sup>); physical activity (study-specific tertiles of metabolic equivalents in hours/week, if available, or low, moderate, high); race (white, black, Asian, other, for studies that did not match on race); family history of colorectal cancer (yes, no); alcohol consumption (men: 0, >0-<30, ≥30 g/d; women: 0, >0-<15, ≥15 g/d); smoking status (never, former, current); aspirin and/or non-steroidal anti-inflammatory drug use (yes, no for regular use, available for 9 cohorts only); and in women, menopausal status and menopausal hormone therapy (postmenopausal/never hormone use, postmenopausal/former hormone use, postmenopausal/current hormone use, postmenopausal/missing hormone use, premenopausal, perimenopausal or missing menopausal status). For the EPIC, this variable was modeled as postmenopausal/not current hormone use and postmenopausal/current hormone use, and for the JPHC, this was modeled as postmenopausal/never hormone use and postmenopausal/ever hormone use). All covariates included a missing category.